Acute Myeloid Leukemia Patient Registry
Part of Blood & lymphatic, Cancer clinical trials.
This registry collects information from adults with AML diagnosed since 2020. It helps doctors understand and improve treatment for this blood cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with acute myeloid leukemia (AML) on or after January 1, 2020.
- You are 18 years old or older.
- You agree to sign a consent form allowing your medical information to be collected.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how acute myeloid leukemia behaves over time in adults and may help doctors better predict outcomes. You might be eligible if you have AML and agree to take part in research.
This study looks at infections in people with newly diagnosed acute myeloid leukemia (AML) starting from March 2025. It aims to understand how often infections happen and how they affect patients, so doctors can improve care.
This study uses advanced genetic analysis to better understand risk in people newly diagnosed with acute myeloid leukemia (AML) at a specific hospital. It may help tailor future treatments.
This study enrolls adults with acute myeloid leukemia (AML) to build a detailed registry and store biological samples. It helps researchers understand AML better and may support future studies.
This is a research registry that collects information and lab/blood sample data to better understand what acute leukemia looks like biologically and how patients do over time. It may help future treatment decisions, but it does not describe testing a new drug.
This study collects information from people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that developed after cancer treatment. It does not test a new drug but helps doctors learn more about these conditions.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.